The Advisory Committee reviewed data from 40 clinical trials involving more than 6,800 patients with type 2 diabetes, of whom more than 4,600 were treated with liraglutide.The timing of the U.S. Launch of liraglutide will be after the FDA review of the application to be determined.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services. A significant difference to patients, the medical profession and society Headquartered in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries and markets its products in 179 countries. Novo Nordisk’s B shares are listed on stock exchanges in Copenhagen and London. Are are listed on the New York Stock Exchange under the symbol ‘NVO’.‘.. Although organization can change the conditions to suit their needs to suit their needs, be be greater coherence between access policies assist researchers to divide samples and data are by confidence that it do this to a manner which consistent to foster with regulatory demands. Mr. Chris Carrigan, head of the NCIN, said: ‘The objective of this document is the person responsible the responsible sharing of data and sampling the benefit of all: patients, the public and the scientific community.